CHI Announces Archimedes Sponsorship & Presentation at CHI’s Phase III Clinical Trials Forum

Jan. 17, 2012 - PRLog -- Cambridge Healthtech Institute (CHI) today announced that Archimedes is a corporate sponsor and presenter at its inaugural Phase III Clinical Trials: Strategic Decisions for Successful Drugs forum to be held on March 12-13, 2012 at the Crowne Plaza Hotel Downtown, Philadelphia, PA.  Badri Rengarajan, M.D., Medical Director, will represent Archimedes.

Dr. Rengarajan will present on avoiding failure and delay: simulation modeling for optimizing design of Phase III trials. This talk is scheduled for Monday, March 13th at 3:00 p.m.  At Archimdes, he is responsible for leading consulting engagements, providing clinical input to Model development efforts, and building relationships with clinical research leaders. Dr. Rengarajan has over ten years of healthcare industry experience including roles in product development strategy and new product planning, regulatory affairs, market research, and business development.

Dr. Rengarajan was previously a director of business development and market research at Nodality (personalized/predictive medicine), regulatory team leader at Genentech, and an engagement manager at McKinsey. Dr. Rengarajan earned an A.B. in biology and public policy.

For more details and to register, please visit http://www.healthtech.com/ph3

To inquire about sponsoring and/or exhibiting, contact Carol Dinerstein, 781-972-5471, dinerstein@healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com